Literature DB >> 18405742

Higher than expected association of clinical prostate and bladder cancers.

Amar Singh1, Yoshihisa Kinoshita, Peter M Rovito, Steve Landas, Jon Silberstein, Imad Nsouli, Ching Y Wang, Gabriel P Haas.   

Abstract

PURPOSE: In this study we evaluated the risk of a second malignancy of the bladder or prostate in patients with a previous diagnosis of prostate cancer (PCa) or urothelial cancer (TCC).
MATERIALS AND METHODS: We retrospectively analyzed all cases of PCa and TCC diagnosed between January 1996 and June 2003. Only PCa diagnosed due to abnormal digital rectal examination or increased prostate specific antigen were included. All patients with TCC presented with hematuria or irritative voiding symptoms and the diagnoses were confirmed with a tissue diagnosis. The incidence of lung, colon and renal cancers was also analyzed.
RESULTS: A total of 816 men were diagnosed with PCa and/or TCC. Of 673 men initially diagnosed with PCa 21 had TCC. Of 149 men initially diagnosed with TCC 18 had PCa. Average age at PCa and TCC diagnosis +/- SD was 68.2 +/- 7.9 and 68.2 +/- 10.4 years, respectively. The standardized incidence ratio (SIR) of TCC in patients with PCa (SIR 4.31, 95% CI 2.411 to 7.110) and of PCa in patients with TCC (SIR 3.83, 95% CI 1.911 to 6.858) was significantly increased. There was no statistical significant difference in SIR for TCC in men with or without radiotherapy. SIR for lung, renal or colon cancer was not significantly different from what was expected.
CONCLUSIONS: Patients with PCa have higher incidence of bladder cancer and those with bladder cancer have a higher incidence of PCa. This study has clinical implications in the care of these patients and it may stimulate research interest that may identify common pathways of carcinogenesis.

Entities:  

Year:  2008        PMID: 18405742     DOI: 10.1016/j.juro.2008.03.130

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Incidental prostate cancer prevalence at radical cystoprostatectomy--importance of the histopathological work-up.

Authors:  C Wetterauer; M Weibel; J R Gsponer; T Vlajnic; T Zellweger; S Bütikofer; G Müller; H Püschel; A Bachmann; T C Gasser; L Bubendorf; C A Rentsch
Journal:  Virchows Arch       Date:  2014-10-01       Impact factor: 4.064

2.  Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy.

Authors:  Shulin Wu; Sharron X Lin; Min Lu; Alexander O Subtelny; Zongwei Wang; Douglas M Dahl; Aria F Olumi; Chin-Lee Wu
Journal:  Int Urol Nephrol       Date:  2019-06-10       Impact factor: 2.370

3.  Bladder cancer in cancer patients: population-based estimates from a large Swedish study.

Authors:  J Lorenzo Bermejo; J Sundquist; K Hemminki
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

4.  A population-based comparison of second primary cancers in Germany and Sweden between 1997 and 2006: clinical implications and etiologic aspects.

Authors:  Hao Liu; Kari Hemminki; Jan Sundquist; Bernd Holleczek; Alexander Katalinic; Katharina Emrich; Lina Jansen; Hermann Brenner
Journal:  Cancer Med       Date:  2013-08-27       Impact factor: 4.452

5.  Prostate cancer as a first and second cancer: effect of family history.

Authors:  H Zhang; J L Bermejo; J Sundquist; K Hemminki
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

6.  Racial differences in the risk of second primary bladder cancer following radiation therapy among localized prostate cancer patients.

Authors:  Lu Zhang; Mei-Chin Hsieh; Claire Allison; Michael Devane; Chindo Hicks; Qingzhao Yu; Lu Shi; Jiande Wu; Xiao-Cheng Wu
Journal:  Cancer Epidemiol       Date:  2021-06-17       Impact factor: 2.890

Review 7.  Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.

Authors:  Christopher J D Wallis; Alyson L Mahar; Richard Choo; Sender Herschorn; Ronald T Kodama; Prakesh S Shah; Cyril Danjoux; Steven A Narod; Robert K Nam
Journal:  BMJ       Date:  2016-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.